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Abstract
Background: Synovial explants furnish an in-situ population of mesenchymal stem cells for the repair of articular cartilage.
Although bone morphogenetic protein 2 (BMP-2) induces the chondrogenesis of bovine synovial explants, the cartilage
formed is neither homogeneously distributed nor of an exclusively hyaline type. Furthermore, the downstream
differentiation of chondrocytes proceeds to the stage of terminal hypertrophy, which is inextricably coupled with
undesired matrix mineralization. With a view to optimizing BMP-2-induced chondrogenesis, the modulating influences of
fibroblast growth factor 2 (FGF-2) and transforming growth factor beta 1 (TGF-ß1) were investigated.
Methodology/Principal Findings: Explants of bovine calf metacarpal synovium were exposed to BMP-2 (200 ng/ml) for 4
(or 6) weeks. FGF-2 (10 ng/ml) or TGF-ß1 (10 ng/ml) was introduced at the onset of incubation and was present either
during the first week of culturing alone or throughout its entire course. FGF-2 enhanced the BMP-2-induced increase in
metachromatic staining for glycosaminoglycans (GAGs) only when it was present during the first week of culturing alone.
TGF-ß1 enhanced not only the BMP-2-induced increase in metachromasia (to a greater degree than FGF-2), but also the
biochemically-assayed accumulation of GAGs, when it was present throughout the entire culturing period; in addition, it
arrested the downstream differentiation of cells at an early stage of hypertrophy. These findings were corroborated by an
analysis of the gene- and protein-expression levels of key cartilaginous markers and by an estimation of individual cell
volume.
Conclusions/Significance: TGF-ß1 enhances the BMP-2-induced chondrogenesis of bovine synovial explants, improves the
hyaline-like properties of the neocartilage, and arrests the downstream differentiation of cells at an early stage of
hypertrophy. With the prospect of engineering a mature, truly articular type of cartilage in the context of clinical repair, our
findings will be of importance in fine-tuning the stimulation protocol for the optimal chondrogenic differentiation of
synovial explants.
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Introduction
Articular cartilage is characterized by unique architectural and
compositional properties which reflect its highly specialized
biomechanical functions within synovial joints. These morpholog-
ical and biochemical peculiarities are, however, achieved at a high
cost: adult tissue that has been injured by trauma or disease
possesses a very limited capacity for self-repair. In young adults,
structural damage to the articular-cartilage layer is a common
consequence of sports injuries, occupational accidents and obesity
[1–3], whereas in elderly individuals, it is one of the early
manifestations of degenerative joint diseases, including osteoar-
thritis [4].
Various tissue-engineering approaches are now being pursued
with a view to promoting the repair of articular-cartilage lesions
[5,6]. Owing to their great capacity for self-renewal, strong
chondrogenic potential and accessibility, mesenchymal stem cells
(MSCs) are an attractive option for the engineering of cartilage
tissue in the context of repair [7,8]. MSCs were originally isolated
from bone marrow [9], but they are now known to reside within
many different mammalian tissues, such as the synovium,
periosteum, trabecular bone, articular cartilage, muscle and fat
[10–17]. Under appropriate stimulation conditions in vitro, MSCs
can differentiate into several tissue types of mesenchymal origin,
including bone, cartilage and fat.
By virtue of its location within the joint cavity, the synovium
would be an ideal source of MSCs for the repair of articular-
cartilage lesions. Both the synovium and articular cartilage develop
from a common pool of MSCs [18]. Hence, MSCs of synovial
origin might give rise to a type of articular cartilage that is more
joint-specific than that formed from those of an ontogenically
unrelated tissue source. Moreover, given that MSCs originating
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from the synovium have been shown to have a higher
chondrogenic capacity than those derived from either bone
marrow, periosteum, fat or muscle [19], and that this tissue can
undergo spontaneous repair after its damage or partial removal
[20–22], strips could be excised and directly autotransplanted to
the defect site, thereby obviating the need to isolate the MSCs and
to expand them in vitro. Furthermore, the physiological scaffold
that is afforded by the synovial extracellular matrix might be more
conductive to chondrogenic differentiation than an artificial
carrier or a natural one that has been derived from a non-joint-
associated tissue. In line with this tenet are the observations that
the synovium can differentiate into cartilaginous tissue under both
clinicopathological [23,24] and experimental conditions [25–27],
as well as our own findings: in previous studies, explants of
synovial tissue were shown to be capable of forming a more
abundant cartilaginous matrix than isolated synovial cells that had
been cultured in alginate or as aggregates [27–30].
In previous studies of ours [27,30], the chondrogenic differen-
tiation of MSCs was shown to be influenced by their tissue source
(synovium vs. bone marrow), by the absence or the presence of
their natural extracellular matrix (aggregates of isolated cells vs.
tissue explants), by the nature of the stimulant [bone morphoge-
netic protein 2 (BMP-2) vs. transforming growth factor beta 1
(TGF-ß1)], and by the inclusion or the exclusion of the modulating
agent dexamethasone (DEX). Hence, in order to elaborate a
synovial-explant-based system for the repair of cartilage, it will be
necessary to delineate an optimal stimulation protocol for the
formation of a hyaline type of tissue.
In the aforementioned studies [27,30], BMP-2 was shown to
induce the chondrogenic differentiation of cultured bovine
synovial explants only when DEX was excluded from the medium.
Since BMP-2 was more potent than TGF-ß1 in inducing not only
the expression of the gene for type-II collagen but also the post-
translational production and secretion of the protein itself, it would
appear to be the more promising candidate of the two for the
generation of a hyaline type of cartilage from synovial explants.
However, BMP-2 alone was unable to effect the complete
differentiation of synovial explants into a typically hyaline type
of articular cartilage throughout the entire tissue volume.
Moreover, the synovial cells underwent full downstream differen-
tiation into the terminal hypertrophic state, which is tantamount to
calcification of the extracellular matrix. Uninterrupted hypertro-
phy carried to completion is characteristic of growth-plate
cartilage [31,32], in which it is a necessary precondition for
mineralization and the longitudinal growth of bones. But in
articular cartilage, hypertrophy is arrested at an early stage
[33,34], specifically to avert matrix mineralization. Hence, for the
generation of a hyaline type of articular cartilage from synovial
explants, the use of BMP-2 as the sole stimulant does not suffice.
We hypothesize that the simultaneous application of an additional
– modulating – agent is needed to optimize the BMP-2-induced
generation of cartilaginous tissue from synovial explants.
It was the aim of the present study to ascertain whether the
BMP-2-induced chondrogenesis of bovine synovial explants could
be qualitatively influenced by the application of one of two
different modulating chondrogenic agents, namely, TGF-ß1 or
fibroblast growth factor 2 (FGF-2). Our data revealed that when
BMP-2 was applied together with TGF-ß1, the synovial explants
underwent a more thorough and homogenous differentiation into
cartilaginous tissue. FGF-2 exerted no such effect. Furthermore,
the downstream differentiation of the cells was arrested at an early
stage of hypertrophy, and the hyaline-like properties of the
neocartilage were improved.
Materials and Methods
Preparation and culturing of synovial explants
Synovial tissue was harvested from the metacarpal joints of 3- to
5-month-old bovine calves. The joints were purchased from a local
butcher no later than 24 hours after the animals had been
slaughtered. [For the use of such cadaver material, no approval by
the cantonal authorities for animal experiments is required, since
these are defined in the International Animal Welfare Act
(Chapter 1, Article 3), as well as in the Swiss Animal Welfare
Regulation (Article 3), as drawing on living organisms.] After
washing, the material was cut into narrow tissue strips (3–5 mm in
width65–7 mm in length61–2 mm in height) under sterile
conditions. These explants were then sandwiched between two
layers of agarose in 24-well tissue-culture plates, as previously
described [27]. Each agarose-sandwiched explant was covered
with 1 ml of serum-free medium [high-glucose Dulbecco’s
modified Eagle medium (Invitrogen, Scotland, UK) containing
1% ITS+TMPremix (BD Biosciences, Bedford, MA), 1 mM proline
(Sigma-Aldrich, St Louis, MO), ascorbic acid (50 mg/ml; Sigma-
Aldrich) and gentamycin (50 mg/ml; Invitrogen). To induce
chondrogenesis, the synovial explants were cultured for 4 (in
selected cases for 6) weeks in the presence of BMP-2 [200 ng/ml; a
generous gift from Pfizer (formerly Wyeth)]. FGF-2 (10 ng/ml;
Calbiochem/Merck Biosciences, Darmstadt, Germany) or TGF-
ß1 (10 ng/ml; Peprotech, Rocky Hill, NJ, USA) was introduced at
the onset of the incubation and was present either during the first
week of culturing alone or throughout the entire culturing period
(4 or 6 weeks). In some instances, the synovial explants were
exposed for 4 weeks to higher concentrations of BMP-2 (600 ng/
ml or 2000 ng/ml). The growth factors were freshly re-introduced
every 2 days when the medium was exchanged. The medium was
supplemented with fresh ascorbic acid (25 mg/ml) on a daily basis.
The synovial explants were cultured at 37uC in a humidified
atmosphere containing 5% CO2.
Histology and Histomorphometry
After culturing, the tissue explants were chemically fixed in
phosphate-buffered saline (pH 7.4) containing 2% formaldehyde,
and then embedded in paraffin. 5-mm-thick sections of the
embedded material were prepared and stained with 1% Toluidine
Blue (pH 2.5) for the histochemical detection of sulphated
proteoglycans within a cartilaginous matrix (an indirect measure
of chondrogenic differentiation). The sections were evaluated in a
Nikon Eclipse E1000 light microscope using a DXM 1200F digital
camera and Eclipsenet software (Nikon, Tokyo, Japan). The
volume fraction of metachromasia in the tissue explants was
assessed morphometrically, as previously described [27]. Individ-
ual cell (lacuna) volume was morphometrically estimated using the
point-sampled intercept methodology [35] in conjunction with a
systematic random-sampling protocol [36].
Immunohistochemistry
Immunohistochemistry was performed on 5-mm-thick paraffin-
embedded sections through the tissue explants, as previously
described [27]. Murine monoclonal antibodies against aggrecan
(clone HAG7D4, Serotec, Oxford, UK), type-II collagen (clone
CII C1, Hybridoma Bank, Iowa City, IA) and type-IX collagen
(clone D1–9, Hybridoma Bank), and lapine polyclonal antibodies
against type-X collagen (ab58632, Abcam plc, Cambridge, UK)
and COMP (a kind gift from Prof. D. Heinega˚rd, Lund University,
Lund, Sweden), were applied. Deparaffinized sections were
exposed first to hyaluronidase [H3506 Sigma-Aldrich (8 mg/ml
of sodium acetate buffer, pH 5.2)] and then to 3% skimmed
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bovine milk containing 1.5% equine or caprine serum to block
non-specific antibody reactivity. Thereafter, they were incubated
with one of the primary antibodies for 60 minutes at 37uC. A
biotinylated form of an equine, anti-murine secondary antibody
(Vector Laboratories, Burlingame, CA) was used to detect the
antibodies against aggrecan, type-II collagen and type-IX colla-
gen. A biotinylated form of a caprine, anti-lapine secondary
antibody (Vector Laboratories) was applied to detect the
antibodies against type-X collagen and COMP. Endogenous
peroxidase activity was blocked with hydrogen peroxide. Immu-
noreactivity was enhanced by applying first the avidin-biotin-
peroxidase complex (Vector Laboratories) and then biotinyl
tyramide (Perkin Elmer, Waltham, MA, USA). Cell nuclei were
counterstained with haematoxylin. The sections were evaluated
and photographed in a Nikon Eclipse E1000 light microscope.
Measurement of GAG-content
After culturing, the tissue explants were digested (overnight at
60uC) with 0.1% papain (Sigma-Aldrich) and 0.1% proteinase K
(Sigma-Aldrich) in 1 mM CaCl2 containing 10 mM TRIS-HCl
(pH 8) as a buffer [37]. The DNA-content of the digests was
measured spectrofluorometrically using the High-Sensitivity
Quant-iTTTM DNA Assay Kit (Molecular Probes, Eugene, OR).
The GAG-content of the digests was determined colorimetrically
after treatment with 1,9-Dimethylmethylene Blue (SERVA
Electrophoresis, Heidelberg, Germany) [38]. Chondroitin sulphate
(Sigma-Aldrich) was used as a standard. The weight of GAGs (in
mg) was expressed per mg of DNA, as well as per mg of the initial
wet weight of the explant.
RNA extraction, reverse transcription and real-time PCR
After culturing, the tissue explants were stored at -70uC in
RNAlaterTM (Qiagen, Hilden, Germany). Prior to real-time PCR
(Applied Biosystems 7900 instrument, Foster City, CA), the RNA
was first isolated from samples that had been pulverized in a
freezer-mill and then reverse transcribed using the Reverse
Transcription System (Promega, Madison, WI), as previously
described [27,39]. An arbitrary calibrator was prepared from a
mixture of the RNA that was isolated from the cartilage and the
synovium of bovine metacarpal joints. Primers and probes were
generated as previously described [30,39]. Gene expression was
normalized to the level of 18S rRNA using the formula 2{DCT ,
where CT is the threshold cycle and DCT = CT (target gene)2CT
(18S rRNA). For each gene, the normalized level of mRNA in
each sample was calculated relative to that in the calibrator
(mixture of uncultured cartilage and synovium) using the formula
2{DDCT , where DDCT =DCT (sample)2DCT (calibrator).
Statistical analysis
Numerical data are represented as mean values together with
the standard error of the mean (SEM). Comparisons between two
sets of data were statistically appraised by an analysis of variances
(ANOVA). Comparisons between multiple groups were evaluated
by applying Dunnett’s multiple comparison test. Statistical
analyses were performed using SPSS software, version 11. 04
(SPSS Inc., Chicago, IL, USA). Statistical significance was set at a
p-value of ,0.05.
Results
Influence of FGF-2 on the BMP-2-induced
chondrogenesis of synovial explants: histological,
histochemical and biochemical evaluation
Synovial explants that had been cultured for 4 weeks in the
absence of a growth factor evinced no signs of metachromasia after
staining with Toluidine Blue (Figure 1A), and the morphology of
the cells remained unchanged. Those that had been exposed to
BMP-2 (200 ng/ml) for a like period (4 weeks) manifested marked
metachromatic staining of the extracellular matrix and cell
differentiation into chondrocytes, which were typically surrounded
by pericellular lacunae (Figures 1A, 3C). The boundary of each
lacuna adumbrates the space originally occupied by the enclosed
cell prior to its shrinkage during chemical processing [40]. The
volume fraction of metachromasia varied between 10 and 20% of
the total explant volume (Figures 1B, 1C, 3A, 3B). The process
of chondrocytic differentiation had progressed to a later stage of
hypertrophy than is characteristic of native articular cartilage, as
evidenced by the larger mean individual cell (lacuna) volume
(Figures 1A, 3C). However, in this in-vitro model, the extracel-
lular matrix did not undergo calcification [as evidenced histo-
chemically after staining with von Kossa’s reagent [41]; data not
shown].
To assess the influence of FGF-2 on the BMP-2-induced
chondrogenesis of synovial explants, this agent (10 ng/mL) was
invariably introduced at the onset of incubation and was thereafter
present either during the first week of culturing alone or
throughout the entire 4-week culturing period. The effects of
FGF-2 were tested both in the absence of BMP-2 and in its
presence throughout the entire 4-week culturing period. In the
absence of BMP-2, exposure of explants to FGF-2 during the first
week of culturing alone led to weak metachromatic staining of the
extracellular matrix but to no change in cell morphology
(Figure 1B, left). The volume fraction of metachromasia was
significantly lower than that achieved after exposure to BMP-2
alone (4 weeks) (Figure 1B, graph). In the presence of BMP-2 (4
weeks), exposure of explants to FGF-2 during the first week of
culturing alone elicited a degree of metachromatic staining that
was qualitatively similar to that achieved after exposure to BMP-2
alone (4 weeks); the attained stage of chondrocytic differentiation
was likewise comparable [qualitatively similar cell (lacuna)-profile
diameters] (Figures 1A, 1B). However, quantification of the
volume fraction of metachromasia revealed this parameter to be
1.8-fold higher (p,0.05) after exposure to the FGF-2 (1st week)/
BMP-2 (4 weeks) combination than after stimulation with BMP-2
alone (Figure 1B, graph).
When explants were exposed to FGF-2 during the entire 4-week
culturing period in the absence of BMP-2, metachromatic staining
of the extracellular matrix was barely detectable and the cells
evinced practically no signs of having been induced to undergo
chondrogenesis (Figure 1C). In the presence of BMP-2 (4 weeks),
exposure to FGF-2 during the entire 4-week culturing period
evoked a degree of metachromasia which, although qualitatively
less intense than that achieved after stimulation with BMP-2 alone
(Figures 1A, 1C), was quantitatively (volume fraction) similar
(Figure 1C, graph). Downstream chondrocytic differentiation had
attained a less advanced stage than was apparent after stimulation
with BMP-2 alone (late hypertrophy), as evidenced by the smaller
cell (lacuna)-profile diameters (Figures 1A, 1C).
Since a limited, 1-week exposure to FGF-2 significantly
enhanced the BMP-2-induced increase in the volume fraction of
metachromasia, explants that had been so treated, as well as the
corresponding positive and negative controls, were subjected to a
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quantitative biochemical analysis of their GAG-contents using the
Dimethylmethylene-Blue assay. This parameter was expressed in
mg per mg of the initial wet weight of the explant (Figure 2A) as
well as in mg per mg of DNA (Figure 2B). After stimulation with
BMP-2 alone (4 weeks), the GAG-content of the explants
increased significantly relative to that of the negative control (no
growth factor), irrespective of whether it was expressed per mg of
the initial wet weight of the tissue or per mg of DNA. Exposure to
FGF-2 alone (1st week) elicited no increase in the GAG-content of
the explants relative to that of the negative control, and when this
agent was introduced (for 1 week) in the presence of BMP-2 (4
weeks), it did not potentiate the increase in this parameter that was
achieved after stimulation with BMP-2 alone (Figures 2A, 2B).
The DNA-content of the explants (expressed in mg per mg of the
initial wet weight of the explant) increased significantly after
exposure to the FGF-2 (1st week)/BMP-2 (4 weeks) combination,
but not after stimulation with either FGF-2 alone (1st week) or
BMP-2 alone (4 weeks) (Figure 2C).
Influence of TGF-ß1 on the BMP-2-induced
chondrogenesis of synovial explants: histological,
histochemical and biochemical evaluation
To assess the influence of TGF-ß1 on the BMP-2-induced
chondrogenesis of synovial explants, this agent (10 ng/ml) was
invariably introduced at the onset of incubation and was thereafter
present either during the first week of culturing alone or
throughout the entire 4-week culturing period. The effects of
TGF-ß1 were tested both in the absence of BMP-2 and in its
Figure 1. Influence of FGF-2 on the BMP-2-induced chondrogenesis of synovial explants (histochemical and histomorphometric
analysis). A–C: Light micrographs of Toluidine-Blue-stained sections through bovine explants that had been cultured for 4 weeks under the
indicated stimulation conditions, and graphs depicting the volume fraction of metachromasia in each case. In A, an image of metacarpal-joint
cartilage is included as a positive control. BMP-2 was applied at a concentration of 200 ng/ml, and FGF-2 at one of 10 ng/ml. In the graphs, mean
values for n=4 animals (4 explants in each case) are represented together with the SEM. n.d.: not detectable; *: p,0.05 vs. ‘‘BMP-2’’ alone.
Bars = 100 mm.
doi:10.1371/journal.pone.0053086.g001
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presence throughout the entire 4-week culturing period. In the
absence of BMP-2, exposure of explants to TGF-ß1 during the first
week of culturing alone elicited no metachromatic staining of the
extracellular matrix and no change in cell morphology
(Figure 3A). In the presence of BMP-2 (4 weeks), exposure of
explants to TGF-ß1 during the first week of culturing alone led to
intense metachromatic staining of the extracellular matrix and to a
differentiation of the cells into chondrocytes, which were typically
surrounded by pericellular lacunae. Although the volume fraction
of metachromasia tended to be higher than that achieved after
stimulation with BMP-2 alone, the two mean values did not differ
significantly from each other (Figure 3A, graph). The process of
chondrocytic differentiation had progressed to the stage of late
hypertrophy, as was the case after stimulation with BMP-2 alone
(Figures 1A, 3A).
When explants were exposed to TGF-ß1 during the entire 4-
week culturing period in the absence of BMP-2, metachromatic
staining of the extracellular matrix was very weak and the cells
evinced practically no signs of having been induced to undergo
chondrogenesis (Figure 3B, left). In the presence of BMP-2 (4
weeks), exposure of explants to TGF-ß1 during the entire 4-week
culturing period led to very intense metachromatic staining of the
extracellular matrix. The volume fraction of metachromasia was
4.8-fold higher than that achieved after stimulation with BMP-2
alone (Figure 3B, graph). The cells had differentiated into
chondrocytes, which were typically surrounded by pericellular
lacunae. However, the process of chondrocytic differentiation had
been arrested at an earlier stage of hypertrophy than was apparent
after stimulation with BMP-2 alone, as evidenced by the smaller
cell (lacuna)-profile diameters (Figures 1A, 3B). To confirm this
qualitative impression, the volumes of the cells (lacunae) were
morphometrically estimated according to stereological principles
after culturing the explants in the presence of either BMP-2 alone
(4 weeks) or the TGF-ß1 (4 weeks)/BMP-2 (4 weeks) combination.
Figure 3C depicts, side by side, the typical appearance of explants
that had been exposed to the two different protocols (left) and the
results of the morphometric analysis of individual cell (lacuna)
volume (right). The numerical data confirm the qualitative
impression: the mean volume of the chondrocytes (lacunae) within
explants that had been exposed to the TGF-ß1 (4 weeks)/BMP-2
(4 weeks) combination was smaller by a factor of 4 than those
within explants that had been stimulated with BMP-2 alone.
We also investigated the influence of raising the concentration
of BMP-2 when this agent was applied as the sole stimulant. Not
only the intensity (Figure 4, left), but also the volume fraction of
metachromasia increased in a dose-dependent manner, from 15%
at 200 ng/ml, through 38% at 600 ng/ml, to 55% at 2000 ng/ml
(Figure 4, graph). When explants were exposed to a combination
of BMP-2 at 200 ng/ml (4 weeks) and TGF-ß1 at 10 ng/ml (4
weeks), the volume fraction of metachromasia (60%) was similar to
that achieved after stimulation with BMP-2 alone (4 weeks) at a
10-fold higher concentration (2000 ng/ml). The volume fraction
of metachromasia within explants that had been exposed to TGF-
ß1 alone (10 ng/ml; 4 weeks) was comparable to that achieved
Figure 2. Influence of FGF-2 on the BMP-2-induced accumulation of GAGs in synovial explants (biochemical analysis). A, B: Graphs
depicting the GAG-content of explants that had been cultured for 4 weeks under the indicated stimulation conditions, expressed either in mg per mg
of the initial wet weight of the tissue sample (A) or in mg per mg of DNA (B). C: Graph depicting the DNA-content of explants that had been cultured
for 4 weeks under the indicated stimulation conditions, expressed in mg per mg of the initial wet weight of the tissue sample. BMP-2 was applied at a
concentration of 200 ng/ml, and FGF-2 at one of 10 ng/ml. Mean values for n= 4 animals (4 explants in each case) are represented together with the
SEM. #: p,0.05 vs. ‘‘No factor’’; ##: p,0.01 vs. ‘‘No factor’’; *: p,0.05; **: p,0.01.
doi:10.1371/journal.pone.0053086.g002
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Figure 3. Influence of TGF-ß1 on the BMP-2-induced chondrogenesis of synovial explants (histochemical and histomorphometric
analysis). A, B: Light micrographs of Toluidine-Blue-stained sections through bovine explants that had been cultured for 4 weeks under the
indicated stimulation conditions (left), and graphs depicting the volume fraction of metachromasia in each case (right). BMP-2 was applied at a
concentration of 200 ng/ml, and TGF-ß1 at one of 10 ng/ml. C: Light micrographs (left) of Toluidine-Blue-stained sections through bovine synovial
explants that had been cultured for 4 weeks in the presence either of BMP-2 alone or of the TGF-ß1/BMP-2 combination, illustrating the size
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after stimulation with BMP-2 alone (4 weeks) at the lowest
concentration (200 ng/ml).
To confirm the potentiating effect of TGF-ß1 (10 ng/ml; 4
weeks) on the BMP-2-induced chondrogenesis of synovial explants
at the lowest concentration of the latter agent (200 ng/ml; 4
weeks), we quantified the GAG-content of the tissue in the relevant
groups (Figure 5). After stimulation with BMP-2 alone (200 ng/
ml; 4 weeks), the GAG-content of the explants increased
significantly relative to that in the negative control (no growth
factor), irrespective of whether it was expressed per mg of the
initial wet weight of the tissue or per mg of DNA (Figures 5A,
5B). Stimulation with TGF-ß1 alone (10 ng/ml; 4 weeks) led to a
similar increase in the GAG-content of the explants, irrespective of
whether it was expressed per mg of the initial wet weight of the
tissue or per mg of DNA, there being no significant differences
between the groups (p.0.05). However, after stimulation with the
TGF-ß1 (10 ng/ml; 4 weeks)/BMP-2 (200 ng/ml; 4 weeks)
combination, the GAG-content of the explants was significantly
higher than after exposure to BMP-2 alone, irrespective of
whether it was expressed per mg of the initial wet weight of the
tissue (p,0.01; Figure 5A) or per mg of DNA (p,0.05;
Figure 5B). The DNA-content of the explants increased after
exposure to either TGF-ß1 alone or the TGF-ß1/BMP-2
combination, but not after stimulation with BMP-2 alone
(Figure 5C).
Influence of TGF-ß1 on the BMP-2-induced expression of
cartilaginous genes within synovial explants
With a view to optimizing the stimulation conditions that are
requisite for driving the chondrogenic differentiation of synovial
explants into a hyaline type of articular cartilage, we monitored
the gene-activity levels of a panel of selected markers after
exposing the tissue to either BMP-2 alone (200 ng/ml), TGF-ß1
alone (10 ng/ml), or the TGF-ß1 (10 ng/ml)/BMP-2 (200 ng/ml)
combination for 4 or 6 weeks. Figure 6 depicts the volume
fraction of metachromasia in each of the 3 groups at both time-
points. Although this parameter tended to increase in a time-
dependent manner in each group, the temporal differences did not
attain statistical significance (p.0.05). The culturing period was
extended from 4 to 6 weeks with a view to registering the gene
activity for type-X collagen (a marker of chondrocytic hypertrophy
[42–44]), which is raised to detectable levels only after the 4th week
of incubation [27]. In each group, the applied growth factors were
present throughout the entire culturing period (4 or 6 weeks).
After stimulation with BMP-2 alone for 4 or 6 weeks, the gene-
expression levels of type-II collagen, type-IX collagen, aggrecan
and Sox9 increased significantly in a time-dependent manner
difference between the cell (lacuna) profiles in each case. The average cell (lacuna) volume was estimated histomorphometrically (right). Mean values
for n=4 animals (4 explants in each case) are represented together with the SEM. n.d.: not detectable; **: p,0.01 vs. ‘‘BMP-2’’. Bars = 100 mm.
doi:10.1371/journal.pone.0053086.g003
Figure 4. Dose-dependency of the BMP-2-induced chondrogenic differentiation of synovial explants. Light micrographs (left) of
Toluidine-Blue-stained sections through explants that had been cultured for 4 weeks in the presence of BMP-2 at 200 ng/ml, 600 ng/ml or 2000 ng/
ml, and graph (right) depicting the volume fraction of metachromasia in each case, as well as within explants that had been exposed for 4 weeks
either to TGF-ß1 alone (10 ng/ml) or to the TGF-ß1 (10 ng/ml)/BMP-2 (200 ng/ml) combination. In the graph, mean values for n=4 animals (4
explants in each case) are represented together with the SEM. n.d.: not detectable; **: p,0.01 vs. ‘‘BMP-2 (200 ng/ml)’’. Bars = 100 mm.
doi:10.1371/journal.pone.0053086.g004
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relative to those in the control group (no growth factor) (Figure 7).
The gene-expression levels of collagen types X and XI increased
significantly only between the 4th and the 6th weeks. After
stimulation with TGF-ß1 alone for 4 weeks, a different pattern of
gene activity was revealed: the levels of type-XI collagen,
aggrecan, COMP and Sox9 increased significantly, whereas those
of type-X collagen decreased. An extension of the culturing period
from 4 to 6 weeks led to further increases in the gene-expression
levels of aggrecan, COMP and Sox9, and to a significant decrease
in that of type-I collagen. Hence, in comparison with the situation
pertaining after exposure to BMP-2 alone, stimulation with TGF-
ß1 alone led, after 4 weeks, to an enhancement in the gene-
expression level of COMP, but to a lowering in that of type-IX
collagen, and, after 6 weeks, likewise to an enhancement in the
gene-expression level of COMP, but to a lowering in that of each
collagen type except type XI. After stimulation with the TGF-ß1/
BMP-2 combination for 4 weeks, the gene-expression levels of
aggrecan and COMP were significantly higher, whereas those of
collagen types IX and X were significantly lower, than after
stimulation with BMP-2 alone. When the culturing period was
extended from 4 to 6 weeks, the gene-expression level of COMP
was higher, whereas those of collagen types I, IX and X were
lower, than after stimulation with BMP-2 alone.
Figure 5. Influence of TGF-ß1 on the BMP-2-induced accumulation of GAGs in synovial explants (biochemical analysis). A, B: Graphs
depicting the GAG-content of explants that had been cultured for 4 weeks under the indicated stimulation conditions, expressed either in mg per mg
of the initial wet weight of the tissue sample (A) or in mg per mg of DNA (B). C: Graph depicting the DNA-content of explants that had been cultured
for 4 weeks under the indicated conditions, expressed in mg per mg of the initial wet weight of the tissue sample. BMP-2 was applied at a
concentration of 200 ng/ml, and TGF-ß1 at one of 10 ng/ml. Mean values for n=4 animals (4 explants in each case) are represented together with the
SEM. #: p,0.05 vs. ‘‘No factor’’; ##: p,0.01 vs. ‘‘No factor’’; *: p,0.05; **: p,0.01.
doi:10.1371/journal.pone.0053086.g005
Figure 6. Influence of culturing time on the volume fraction of
metachromasia in chondrogenically-stimulated synovial ex-
plants. Bovine explants were cultured for 4 or 6 weeks under the
indicated stimulated conditions. BMP-2 was applied at a concentration
of 200 ng/ml, and TGF-ß1 at one of 10 ng/ml. Each agent was
introduced at the onset of the incubation and was present throughout
its course. Mean values for n= 4 animals (4 explants in each case) are
represented together with the SEM. n.d.: not detectable.
doi:10.1371/journal.pone.0053086.g006
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Influence of TGF-ß1 on the BMP-2-induced deposition of
cartilaginous proteins within synovial explants
An immunohistochemical analysis was conducted to evaluate
the modulatory effects of TGF-ß1 on the BMP-2-induced post-
translational production and secretion of key cartilaginous
proteins, namely, aggrecan, collagen types II, IX and X, and
COMP (Figure 8). Synovial explants were cultured for 6 weeks in
the absence of a growth factor (negative control), or in the
Figure 7. Influence of TGF-ß1 on the BMP-2-induced expression of cartilaginous genes in synovial explants. Bovine explants were
cultured for 4 or 6 weeks under the indicated stimulation conditions. BMP-2 was applied at a concentration of 200 ng/ml, and TGF-ß1 at one of
10 ng/ml. Each agent was introduced at the onset of the incubation and was present throughout its course. The expression level of each gene
(determined by a quantitative real-time PCR analysis) was related to that in a calibrator (a mixture of uncultured cartilage and synovium) after
normalization to that of 18S rRNA. Mean values for n= 4 animals (4 explants in each case) are represented together with the SEM. #: p,0.05 vs. ‘‘No
factor’’; ##: p,0.01 vs. ‘‘No factor’’; *: p,0.05 vs. ‘‘BMP-2’’; **:p,0.01 vs. ‘‘BMP-2’’.
doi:10.1371/journal.pone.0053086.g007
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presence of either BMP-2 alone (200 ng/ml), TGF-ß1 alone
(10 ng/ml), or the TGF-ß1 (10 ng/ml)/BMP-2 (200 ng/ml)
combination. In each group, the applied growth factors were
present throughout the entire 6-week culturing period. Bovine
articular cartilage that had been derived from the metacarpal joint
served as a positive control. Within the extracellular matrix of
native articular cartilage, immunoreactivity for aggrecan and type-
II collagen, as well as that for COMP, was observed from the
superficial zone down to the lower radial one (Figure 8).
Immunostaining for type-IX collagen occurred predominantly in
the zone of calcified cartilage, and was more intense in this region
than in any other. Immunoreactivity for type-X collagen was
inhomogeneously distributed throughout the extracellular matrix
in the transitional and the upper radial zones (small cells) (not
illustrated in Figure 8), but was strongest within the pericellular
compartment in the lower radial one (hypertrophic chondrocytes)
(Figure 8).
Synovial explants that had been cultured in the absence of a
growth factor (negative control) revealed no detectable signs of
immunoreactivity for either type-II or type-IX collagen; weak
signals were registered for aggrecan, type-X collagen and COMP.
Explants that had been stimulated with BMP-2 alone registered
positive for each of the tested proteins. After stimulation with
TGF-ß1 alone, immunostaining of the tissue samples was observed
only for aggrecan, not for any of the tested collagen types (II, IX
and X). Immunoreactivity for COMP was confined to the upper
layer of agarose within which the explants were embedded (see
Materials and Methods), and into which some of the peripheral
synovial cells had migrated. Compared to explants that had been
stimulated with BMP-2 alone, those that had been exposed to the
TGF-ß1/BMP-2 combination manifested more homogeneously-
distributed immunoreactivity for aggrecan, type-II collagen, type-
X collagen and COMP; that for type-IX collagen was appreciably
reduced; it was confined to the upper layer of agarose within
which the explants were embedded and to the pericellular matrix
around scattered cells throughout the depth of the tissue samples.
It is noteworthy that in native articular cartilage, immunoreactivity
for type-X collagen occurred predominantly within the pericellular
matrix that surrounded hypertrophic chondrocytes, whereas in the
explants that had been exposed to the TGF-ß1/BMP-2 combi-
nation, it was more homogeneously distributed throughout the
extracellular matrix as a whole and was not confined to any
particular stratum. Although immunoreactivity for type-X colla-
gen was more homogeneously distributed after exposure to the
TGF-ß1/BMP-2 combination than after stimulation with BMP-2
alone, the overall intensity of staining was weaker.
Figure 8. Influence of TGF-ß1 on the BMP-2-induced deposition of cartilaginous proteins in synovial explants (immunohisto-
chemical analysis). Light micrographs of sections through bovine explants that had been cultured for 6 weeks under the indicated stimulation
conditions and then either stained with Toluidine Blue (1st row), or treated for the immunohistochemical detection of aggrecan (2nd row), type-II
collagen (3rd row), type-IX collagen (4th row), type-X collagen (5th row) or COMP (6th row). BMP-2 was applied at a concentration of 200 ng/ml, and
TGF-ß1 at one of 10 ng/ml. Each agent was introduced at the onset of the 6-week culturing period and was present throughout its course. Native
(uncultured) metacarpal-joint cartilage (final vertical column) served as a positive control. Cell nuclei (2nd to 6th rows) were counterstained with
haematoxylin. All photomicrographs are represented at the same final magnification. Bar = 100 mm.
doi:10.1371/journal.pone.0053086.g008
Synovium-Based Chondrogenesis for Cartilage Repair
PLOS ONE | www.plosone.org 10 January 2013 | Volume 8 | Issue 1 | e53086
Discussion
FGF-2 is described in the literature to be a highly potent
mitogen for various cell-types of mesodermal and neuroectoder-
mal origin [45]. For this reason, it is often used to stimulate the
expansion of MSCs in vitro [46,47]. Human bone-marrow-derived
MSCs that have been expanded in the presence of FGF-2 not only
proliferate more rapidly but also manifest a higher chondrogenic
potential than those grown in its absence [48–51]. Similar effects
have been observed for MSCs derived from adipose or synovial
tissue [52,53]. However, if FGF-2 is introduced into the growth
medium at a juncture corresponding to the chondrogenic-
differentiation phase of the MSCs, the reported effects of the
agent are conflicting. On the one hand, FGF-2 has been reported
to enhance the TGF-ß1-induced chondrogenesis of lapine
periosteal explants [54] and of adipose-tissue-derived murine
MSCs [52], whilst on the other, it has been described to suppress
the TGF-ß1-induced – and to completely abolish the potentiating
effect of BMP-6 on the TGF-ß3-induced – chondrogenesis of
adipose-tissue-derived human MSCs [55,56].
In the present study, FGF-2 was applied in combination with
BMP-2 to cultures of bovine synovial explants. When FGF-2 was
applied during the first week of culturing alone, it enhanced the
BMP-2-induced increase in the volume fraction of metachromasia
within the explants, whereas when it was present throughout the
entire 4-week culturing period it did not. We do not yet
understand why the potentiating effect of FGF-2 on the BMP-2-
induced chondrogenesis of synovial explants depends upon the
duration of exposure to the agent. The potential of FGF-2 to
induce variable and even opposing effects in vivo as well as in vitro is,
however, well known. FGFs are essential for skeletal development,
and during this process, their influence has been described to be
both stage- and region-specific [57,58]. Likewise in vitro, FGFs
have been shown to regulate the osteogenic differentiation of
neonatal calvarial osteoblastic cells as well as the chondrogenesis of
bone-marrow-derived MSCs in a stage-specific manner [59,60].
These findings suggest that the expression of FGF-receptors on
osteo- or chondroprogenitor cells is confined to a narrow temporal
window during the process of their differentiation. In our
experimental set-up, this window fell within – and had been
passed through by the end of – the first week of stimulation with
FGF-2.
Although FGF-2 enhanced the BMP-2-induced increase in the
volume fraction of metachromasia within the explants, its
influence was not sufficiently potent to augment the GAG-content
of the tissue samples. TGF-ß1, on the other hand, enhanced not
only the BMP-2-induced increase in the volume fraction of
metachromasia within the explants (in a manner that was not
confined to a temporal window), but also the GAG-content of the
tissue samples. The potentiating effect of TGF-ß1 on the BMP-2-
induced production of GAGs (aggrecan) was confirmed also at the
gene- (Figure 7) and protein- (Figure 8) expression levels. On the
other hand, TGF-ß1 enhanced the BMP-2-induced increase in the
post-translational deposition of type-II collagen without influenc-
ing its gene-expression level. Although we cannot as yet account
for this phenomenon, we suspect that the discrepancy may arise
from a possible interaction between the type-II-collagen protein
and other components of the cartilaginous matrix. COMP, for
example, is known to bind to collagenous proteins [61–63] and to
enhance their fibrillogenesis [64]. In the present study, TGF-ß1
enhanced the BMP-2-induced increase in both the gene- and the
protein-expression levels of COMP. This being the case, it is
conceivable that the type-II-collagen protein – stabilized by
COMP – was retained within, rather than leaching out of, the
cartilaginous matrix, thereby resulting in an immunohistochemical
signal for the protein itself that was disproportionately high relative
to the expression level of its gene.
In combination with BMP-2, TGF-ß1 was capable of arresting,
at an early juncture, the downstream hypertrophic differentiation
of chondrocytes, which, after stimulation with the former agent
alone, progresses to the terminal stage that is inextricably
associated with matrix mineralization. This anti-hypertrophic
effect of TGF-ß1 on the BMP-2-induced chondrogenesis of bovine
synovial explants was discovered by ourselves several years ago,
and although the finding was not documented at the time, it was
communicated in an oral presentation at the 7th World Congress
of the International Cartilage Repair Society (2007). Subsequently,
the effect was confirmed using pellet-cultures of isolated human
synovial MSCs and BMP-7 instead of BMP-2 as a stimulant [65].
The histomorphological findings presented in this publication
were, however, of a descriptive nature only; they were not
substantiated either by histomorphometry or by an analysis of the
gene- and protein-expression levels. In the present study, these
analyses were undertaken. TGF-ß1 was found to suppress the
BMP-2-induced increases in both the gene- (marked effect at 6
weeks) and the protein- (appreciable effect at 6 weeks) expression
levels of type-X collagen, which is a marker of chondrocytic
hypertrophy.
In growth-plate cartilage, the type-X-collagen protein is
expressed predominantly by hypertrophic chondrocytes [42–44],
and its well-known calcium-binding properties appear to play a
role in the mineralization process that they initiate at a late stage of
differentiation [66]. In articular cartilage, on the other hand, the
type-X-collagen protein is expressed not only in the zone of
calcification, but also in other regions of the tissue layer [67,68]. In
the present study, the immunohistochemical analysis of bovine
metacarpal-joint cartilage revealed the type-X-collagen protein to
be expressed throughout the extracellular matrix in the transitional
and the upper radial zones (small cells), but almost exclusively
within the pericellular compartment in the lower radial one
(hypertrophic chondrocytes) (Figure 8). Further investigations will
be necessary to elucidate the biological role of the type-X-collagen
protein in the zones containing the small (non-hypertrophic)
chondrocytes.
In native bovine articular cartilage, the type-IX-collagen protein
was expressed exclusively in the zone of calcification, which
accords with the findings in a porcine model [69], although in
foetal avian sternal cartilage, it is distributed throughout the entire
tissue layer [70]. The role played by type-IX collagen in the zone
of calcification has not been clearly defined. In foetal avian
cartilage, it has been shown to stabilize the cross-linkage of
collagen fibrils [70]. In transgenic mice that lack the type-IX-
collagen gene, skeletal morphogenesis follows a normal course up
to the time of parturition. However, thereafter, when the joints of
the animals have to bear weights, the articular-cartilage layer
undergoes progressive degeneration. This latter finding indicates
that type-IX collagen plays an important role in stabilizing the
mechanical properties of the articular-cartilage layer in weight-
bearing regions [71,72]. In the present study, TGF-ß1 suppressed
the BMP-2-induced increases in both the gene- and the protein-
expression levels of type-IX collagen. Whether this effect is
reflected in a measurable influence on the mechanical stability of
the explants is not yet known, but the issue could be clarified by
subjecting the tissue samples to appropriate biomechanical tests
(currently under investigation).
With a view to the engineering of articular cartilage in the
context of clinical repair, the finding that TGF-ß1 is capable of
arresting the BMP-2-induced downstream differentiation of
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synovial MSCs into chondrocytes at an early stage of hypertrophy
represents an important step towards the generation of a hyaline –
rather than the usual fibrous [73] – type of repair tissue. In vivo, the
complete downstream differentiation of cells into terminal
hypertrophic chondrocytes is inextricably coupled with mineral-
ization of the extracellular matrix. The potency of BMP-2 in
stimulating the chondrogenesis of MSCs is advantageous on the
one hand in that it assures an efficacious differentiation response,
but disadvantageous on the other in so far as the process is
catapulted rather too efficaciously towards completion in the
downstream direction, resulting in what is for articular cartilage a
hypertrophic overshoot but for the growth plate a necessity. In
epiphyseal-plate cartilage, the mean volume of individual terminal
hypertrophic chondrocytes varies between 5,000 and 20,000 mm3,
according to the phase of growth [31,32]. In articular cartilage, the
mean volume of individual hypertrophic chondrocytes in the lower
radial zone (which abuts on the calcified region) ranges from 2,000
to 4,000 mm3 [33,34], with little variation between species [74]. In
the present study, the mean volume of individual chondrocytes in
the explants was 5,600 mm3 after stimulation with BMP-2 alone
and 1,400 mm3 after exposure to the TGF-ß1/BMP-2 combina-
tion (Figure 3), which approximates to the terminal size achieved
in the lower radial zone of native articular cartilage [33,34].
The concomitant application of diverse TGF-ß isoforms and
BMPs has been demonstrated also by other investigators to
potentiate the chondrogenic effects of either agent alone on MSCs.
For example, using bone-marrow-derived human MSCs, BMP-2,
BMP-6 and BMP-7 have been individually shown to enhance
TGF-ß3-induced chondrogenesis, evidence for which was fur-
nished by an up-regulation of the genes for aggrecan and type-II
collagen [75], by an increase in the total weight of the pellets and
in their metachromatic staining for GAGs [76], and by the
deposition of augmented quantities of proteoglycans, type-II
collagen and Sox9 [77]. And also using human MSCs of
adipose-tissue origin, a combination of BMP-7 and TGF-ß2 has
been described to enhance the quantity of GAGs and the
expression of the type-II-collagen gene over and above the levels
that were achieved after stimulation with either of the factors alone
[78]. However, in these earlier reports, no mention was made of
an anti-hypertrophic effect of the applied TGF-ß on BMP-induced
chondrogenesis. The absence of the effect in these former studies
could be attributable to several factors. Firstly, the anti-hypertro-
phic effect of TGF-ßs may depend upon the tissue source of the
MSCs. The responsivity of MSCs to a given growth factor has
indeed been shown to vary according to their tissue origin [30].
Although some of the combined effects of BMP-2 and TGF-ß on
the chondrogenesis of isolated, aggregate-cultured human MSCs
of synovial origin have been described [79,80], an anti-hypertro-
phic influence of the latter agent was not apparent, since the
applied concentration of BMP-2 was too low to induce the full
downstream differentiation of the cells into terminal chondrocytes
[79]. The effects of stimulating with BMP-2 alone were not
documented [80]. Secondly, the anti-hypertrophic effect of TGF-
ßs on MSCs might depend upon the presence of their natural
extracellular matrix. Isolated MSCs are stripped of the niche
information to which they are subject in situ, and their extrication
from it can have a marked influence on their reactivity [30].
Thirdly, the anti-hypertrophic effect exerted by TGF-ßs may
depend upon the nature of the applied isoform, or, fourthly, upon
the concentration at which it is used [81].
Indirect evidence of the anti-hypertrophic effect of TGF-ß1 is,
however, available for other cell systems. For example, using
isolated, aggregate-cultured rat periosteal cells, TGF-ß1 has been
shown to inhibit the BMP-2-induced expression of the genes for
type-X collagen and osteocalcin [82]. Similarly, TGF-ß1 has been
reported to suppress the terminal differentiation of both lapine
[83] and rat [84] growth-plate chondrocytes in vitro. And in living
mice, deletion of the gene for smad3, which is one of the
intracellular mediators of TGF-induced signalling cascades, led to
an enhancement of the terminal differentiation of articular
chondrocytes [85]. This latter finding corroborates those of the
present study. TGF-ß-induced signalling would thus appear to
play a crucial role in regulating the hypertrophy of chondrocytes.
However, whether this effect is exerted in humans and other
primates, as well as in non-primates, remains to be clarified.
In summary, although BMP-2 is capable of inducing the
chondrogenesis of bovine synovial explants, the cartilaginous tissue
formed is neither homogeneously distributed nor of an exclusively
hyaline type, and the process of downstream differentiation
progresses all the way to the stage of terminal hypertrophy (as
occurs physiologically in growth-plate and foetal – but not in
articular – cartilage). TGF-ß1 enhances the BMP-2-induced
chondrogenic differentiation of synovial explants, improves the
hyaline-like properties of the cartilaginous tissue formed, and
arrests the process of hypertrophy at an early stage, which
corresponds to that attained in the lower radial zone of native
articular cartilage.
Acknowledgments
The authors are indebted to Fabienne Bourquin for her technical
assistance. They would also like to thank Pfizer (formerly Wyeth) for
providing them with a supply of recombinant BMP-2, and Prof. Dick
Heinega˚rd (Lund University, Lund, Sweden) for his kind gift of the anti-
COMP antibody.
Author Contributions
Conceived and designed the experiments: NS EBH. Performed the
experiments: NS EBH. Analyzed the data: NS EBH. Wrote the paper: NS
EBH. Critical input: KAS.
References
1. Roos EM (2005) Joint injury causes knee osteoarthritis in young adults. Curr
Opin Rheumatol 17: 195–200.
2. Gelber AC, Hochberg MC, Mead LA, Wang NY, Wigley FM, et al. (2000) Joint
injury in young adults and risk for subsequent knee and hip osteoarthritis. Ann
Intern Med 133: 321–328.
3. Manek NJ, Hart D, Spector TD, MacGregor AJ (2003) The association of body
mass index and osteoarthritis of the knee joint: an examination of genetic and
environmental influences. Arthritis Rheum 48: 1024–1029.
4. Roth RD (1993) Joint diseases associated with aging. Clin Podiatr Med Surg 10:
137–159.
5. Hunziker EB (2002) Articular cartilage repair: basic science and clinical
progress. A review of the current status and prospects. Osteoarthritis Cartilage
10: 432–463.
6. Getgood A, Brooks R, Fortier L, Rushton N (2009) Articular cartilage tissue
engineering: today’s research, tomorrow’s practice? J Bone Joint Surg Br 91:
565–576.
7. Caplan AI (1991) Mesenchymal stem cells. J Orthop Res 9: 641–650.
8. Chen FH, Rousche KT, Tuan RS (2006) Technology Insight: adult stem cells in
cartilage regeneration and tissue engineering. Nat Clin Pract Rheumatol 2: 373–
382.
9. Friedenstein AJ, Piatetzky S, II, Petrakova KV (1966) Osteogenesis in
transplants of bone marrow cells. J Embryol Exp Morphol 16: 381–390.
10. De Bari C, Dell’Accio F, Tylzanowski P, Luyten FP (2001) Multipotent
mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum
44: 1928–1942.
11. No¨th U, Osyczka AM, Tuli R, Hickok NJ, Danielson KG, et al. (2002)
Multilineage mesenchymal differentiation potential of human trabecular bone-
derived cells. J Orthop Res 20: 1060–1069.
Synovium-Based Chondrogenesis for Cartilage Repair
PLOS ONE | www.plosone.org 12 January 2013 | Volume 8 | Issue 1 | e53086
12. Erickson GR, Gimble JM, Franklin DM, Rice HE, Awad H, et al. (2002)
Chondrogenic potential of adipose tissue-derived stromal cells in vitro and in
vivo. Biochem Biophys Res Commun 290: 763–769.
13. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, et al. (2002) Human
adipose tissue is a source of multipotent stem cells. Mol Biol Cell 13: 4279–4295.
14. De Bari C, Dell’Accio F, Vanlauwe J, Eyckmans J, Khan IM, et al. (2006)
Mesenchymal multipotency of adult human periosteal cells demonstrated by
single-cell lineage analysis. Arthritis Rheum 54: 1209–1221.
15. Sinanan AC, Hunt NP, Lewis MP (2004) Human adult craniofacial muscle-
derived cells: neural-cell adhesion-molecule (NCAM; CD56)-expressing cells
appear to contain multipotential stem cells. Biotechnol Appl Biochem 40: 25–34.
16. Mastrogiacomo M, Derubeis AR, Cancedda R (2005) Bone and cartilage
formation by skeletal muscle derived cells. J Cell Physiol 204: 594–603.
17. Alsalameh S, Amin R, Gemba T, Lotz M (2004) Identification of mesenchymal
progenitor cells in normal and osteoarthritic human articular cartilage. Arthritis
Rheum 50: 1522–1532.
18. Archer CW, Dowthwaite GP, Francis-West P (2003) Development of synovial
joints. Birth Defects Res C Embryo Today 69: 144–155.
19. Sakaguchi Y, Sekiya I, Yagishita K, Muneta T (2005) Comparison of human
stem cells derived from various mesenchymal tissues: superiority of synovium as
a cell source. Arthritis Rheum 52: 2521–2529.
20. Gualtieri G, Gambrioli PL (1978) [Surgical treatment of rheumatoid arthritis].
Chir Ital 30: 642–650.
21. Theoret CL, Barber SM, Moyana T, Townsend HG, Archer JF (1996) Repair
and function of synovium after arthroscopic synovectomy of the dorsal
compartment of the equine antebrachiocarpal joint. Vet Surg 25: 142–153.
22. Fowler MR, Nathan CO, Abreo F (2002) Synovial metaplasia, a specialized
form of repair. Arch Pathol Lab Med 126: 727–730.
23. Maurice H, Crone M, Watt I (1988) Synovial chondromatosis. J Bone Joint Surg
Br 70: 807–811.
24. Berg E (1999) Synovial osteochondomatosis. Orthop Nurs 18: 55–56.
25. Elford PR, Graeber M, Ohtsu H, Aeberhard M, Legendre B, et al. (1992)
Induction of swelling, synovial hyperplasia and cartilage proteoglycan loss upon
intra-articular injection of transforming growth factor beta-2 in the rabbit.
Cytokine 4: 232–238.
26. Nishimura K, Solchaga LA, Caplan AI, Yoo JU, Goldberg VM, et al. (1999)
Chondroprogenitor cells of synovial tissue. Arthritis Rheum 42: 2631–2637.
27. Shintani N, Hunziker EB (2007) Chondrogenic differentiation of bovine
synovium: bone morphogenetic proteins 2 and 7 and transforming growth
factor beta1 induce the formation of different types of cartilaginous tissue.
Arthritis Rheum 56: 1869–1879.
28. Park Y, Sugimoto M, Watrin A, Chiquet M, Hunziker EB (2005) BMP-2
induces the expression of chondrocyte-specific genes in bovine synovium-derived
progenitor cells cultured in three-dimensional alginate hydrogel. Osteoarthritis
Cartilage 13: 527–536.
29. Kurth T, Hedbom E, Shintani N, Sugimoto M, Chen FH, et al. (2007)
Chondrogenic potential of human synovial mesenchymal stem cells in alginate.
Osteoarthritis Cartilage 15: 1178–1189.
30. Shintani N, Hunziker EB (2011) Differential effects of dexamethasone on the
chondrogenesis of mesenchymal stromal cells: Influence of microenvironment,
tissue origin and growth factor. Eur Cell Mater 22: 302–320.
31. Hunziker EB, Schenk RK, Cruz-Orive LM (1987) Quantitation of chondrocyte
performance in growth-plate cartilage during longitudinal bone growth. J Bone
Joint Surg Am 69: 162–173.
32. Hunziker EB, Schenk RK (1989) Physiological mechanisms adopted by
chondrocytes in regulating longitudinal bone growth in rats. J Physiol 414:
55–71.
33. Eggli PS, Hunziker EB, Schenk RK (1988) Quantitation of structural features
characterizing weight- and less-weight-bearing regions in articular cartilage: a
stereological analysis of medial femoral condyles in young adult rabbits. Anat
Rec 222: 217–227.
34. Hunziker EB, Quinn TM, Hauselmann HJ (2002) Quantitative structural
organization of normal adult human articular cartilage. Osteoarthritis Cartilage
10: 564–572.
35. Gundersen HJ, Bagger P, Bendtsen TF, Evans SM, Korbo L, et al. (1988) The
new stereological tools: disector, fractionator, nucleator and point sampled
intercepts and their use in pathological research and diagnosis. APMIS 96: 857–
881.
36. Gundersen HJ, Jensen EB (1987) The efficiency of systematic sampling in
stereology and its prediction. J Microsc 147: 229–263.
37. Roche S, Ronziere MC, Herbage D, Freyria AM (2001) Native and DPPA
cross-linked collagen sponges seeded with fetal bovine epiphyseal chondrocytes
used for cartilage tissue engineering. Biomaterials 22: 9–18.
38. Farndale RW, Buttle DJ, Barrett AJ (1986) Improved quantitation and
discrimination of sulphated glycosaminoglycans by use of dimethylmethylene
blue. Biochim Biophys Acta 883: 173–177.
39. Shintani N, Kurth T, Hunziker EB (2007) Expression of cartilage-related genes
in bovine synovial tissue. J Orthop Res 25: 813–819.
40. Hunziker EB, Herrmann W, Schenk RK (1983) Ruthenium hexammine
trichloride (RHT)-mediated interaction between plasmalemmal components and
pericellular matrix proteoglycans is responsible for the preservation of
chondrocytic plasma membranes in situ during cartilage fixation. J Histochem
Cytochem 31: 717–727.
41. Sheehan D, Hrapchak B (1980) Theory and Practice of Histotechnology. Ohio:
Battelle Press. pp 226–227.
42. Schmid TM, Linsenmayer TF (1983) A short chain (pro)collagen from aged
endochondral chondrocytes. Biochemical characterization. J Biol Chem 258:
9504–9509.
43. Kielty CM, Kwan AP, Holmes DF, Schor SL, Grant ME (1985) Type X
collagen, a product of hypertrophic chondrocytes. Biochem J 227: 545–554.
44. Kirsch T, von der Mark K (1991) Isolation of human type X collagen and
immunolocalization in fetal human cartilage. Eur J Biochem 196: 575–580.
45. Gospodarowicz D, Neufeld G, Schweigerer L (1986) Molecular and biological
characterization of fibroblast growth factor, an angiogenic factor which also
controls the proliferation and differentiation of mesoderm and neuroectoderm
derived cells. Cell Differ 19: 1–17.
46. Martin I, Muraglia A, Campanile G, Cancedda R, Quarto R (1997) Fibroblast
growth factor-2 supports ex vivo expansion and maintenance of osteogenic
precursors from human bone marrow. Endocrinology 138: 4456–4462.
47. Deasy BM, Qu-Peterson Z, Greenberger JS, Huard J (2002) Mechanisms of
muscle stem cell expansion with cytokines. Stem Cells 20: 50–60.
48. Banfi A, Muraglia A, Dozin B, Mastrogiacomo M, Cancedda R, et al. (2000)
Proliferation kinetics and differentiation potential of ex vivo expanded human
bone marrow stromal cells: Implications for their use in cell therapy. Exp
Hematol 28: 707–715.
49. Mastrogiacomo M, Cancedda R, Quarto R (2001) Effect of different growth
factors on the chondrogenic potential of human bone marrow stromal cells.
Osteoarthritis Cartilage 9 Suppl A: S36–40.
50. Tsutsumi S, Shimazu A, Miyazaki K, Pan H, Koike C, et al. (2001) Retention of
multilineage differentiation potential of mesenchymal cells during proliferation
in response to FGF. Biochem Biophys Res Commun 288: 413–419.
51. Solchaga LA, Penick K, Porter JD, Goldberg VM, Caplan AI, et al. (2005) FGF-
2 enhances the mitotic and chondrogenic potentials of human adult bone
marrow-derived mesenchymal stem cells. J Cell Physiol 203: 398–409.
52. Chiou M, Xu Y, Longaker MT (2006) Mitogenic and chondrogenic effects of
fibroblast growth factor-2 in adipose-derived mesenchymal cells. Biochem
Biophys Res Commun 343: 644–652.
53. Kim JH, Lee MC, Seong SC, Park KH, Lee S (2011) Enhanced proliferation
and chondrogenic differentiation of human synovium-derived stem cells
expanded with basic fibroblast growth factor. Tissue Eng Part A 17: 991–1002.
54. Stevens MM, Marini RP, Martin I, Langer R, Prasad Shastri V (2004) FGF-2
enhances TGF-beta1-induced periosteal chondrogenesis. J Orthop Res 22:
1114–1119.
55. Hennig T, Lorenz H, Thiel A, Goetzke K, Dickhut A, et al. (2007) Reduced
chondrogenic potential of adipose tissue derived stromal cells correlates with an
altered TGFbeta receptor and BMP profile and is overcome by BMP-6. J Cell
Physiol 211: 682–691.
56. Hildner F, Peterbauer A, Wolbank S, Nurnberger S, Marlovits S, et al. (2010)
FGF-2 abolishes the chondrogenic effect of combined BMP-6 and TGF-beta in
human adipose derived stem cells. J Biomed Mater Res A 94: 978–987.
57. Martin GR (1998) The roles of FGFs in the early development of vertebrate
limbs. Genes Dev 12: 1571–1586.
58. Ornitz DM, Marie PJ (2002) FGF signaling pathways in endochondral and
intramembranous bone development and human genetic disease. Genes Dev 16:
1446–1465.
59. Debiais F, Hott M, Graulet AM, Marie PJ (1998) The effects of fibroblast growth
factor-2 on human neonatal calvaria osteoblastic cells are differentiation stage
specific. J Bone Miner Res 13: 645–654.
60. Hellingman CA, Koevoet W, Kops N, Farrell E, Jahr H, et al. (2010) Fibroblast
growth factor receptors in in vitro and in vivo chondrogenesis: relating tissue
engineering using adult mesenchymal stem cells to embryonic development.
Tissue Eng Part A 16: 545–556.
61. Rosenberg K, Olsson H, Morgelin M, Heinega˚rd D (1998) Cartilage oligomeric
matrix protein shows high affinity zinc-dependent interaction with triple helical
collagen. J Biol Chem 273: 20397–20403.
62. Thur J, Rosenberg K, Nitsche DP, Pihlajamaa T, Ala-Kokko L, et al. (2001)
Mutations in cartilage oligomeric matrix protein causing pseudoachondroplasia
and multiple epiphyseal dysplasia affect binding of calcium and collagen I, II,
and IX. J Biol Chem 276: 6083–6092.
63. Holden P, Meadows RS, Chapman KL, Grant ME, Kadler KE, et al. (2001)
Cartilage oligomeric matrix protein interacts with type IX collagen, and
disruptions to these interactions identify a pathogenetic mechanism in a bone
dysplasia family. J Biol Chem 276: 6046–6055.
64. Halasz K, Kassner A, Morgelin M, Heinega˚rd D (2007) COMP acts as a catalyst
in collagen fibrillogenesis. J Biol Chem 282: 31166–31173.
65. Miyamoto C, Matsumoto T, Sakimura K, Shindo H (2007) Osteogenic protein-
1 with transforming growth factor-beta1: potent inducer of chondrogenesis of
synovial mesenchymal stem cells in vitro. J Orthop Sci 12: 555–561.
66. Kirsch T, von der Mark K (1991) Ca2+ binding properties of type X collagen.
FEBS Lett 294: 149–152.
67. van der Kraan PM, Stoop R, Meijers TH, Poole AR, van den Berg WB (2001)
Expression of type X collagen in young and old C57Bl/6 and Balb/c mice.
Relation with articular cartilage degeneration. Osteoarthritis Cartilage 9: 92–
100.
68. Lammi PE, Lammi MJ, Hyttinen MM, Panula H, Kiviranta I, et al. (2002) Site-
specific immunostaining for type X collagen in noncalcified articular cartilage of
canine stifle knee joint. Bone 31: 690–696.
Synovium-Based Chondrogenesis for Cartilage Repair
PLOS ONE | www.plosone.org 13 January 2013 | Volume 8 | Issue 1 | e53086
69. Wardale RJ, Duance VC (1993) Quantification and immunolocalisation of
porcine articular and growth plate cartilage collagens. J Cell Sci 105 (Pt 4): 975–
984.
70. Muller-Glauser W, Humbel B, Glatt M, Strauli P, Winterhalter KH, et al. (1986)
On the role of type IX collagen in the extracellular matrix of cartilage: type IX
collagen is localized to intersections of collagen fibrils. J Cell Biol 102: 1931–
1939.
71. Fa¨ssler R, Schnegelsberg PN, Dausman J, Shinya T, Muragaki Y, et al. (1994)
Mice lacking alpha 1 (IX) collagen develop noninflammatory degenerative joint
disease. Proc Natl Acad Sci U S A 91: 5070–5074.
72. Hagg R, Hedbom E, Mollers U, Aszodi A, Fassler R, et al. (1997) Absence of the
alpha1(IX) chain leads to a functional knock-out of the entire collagen IX
protein in mice. J Biol Chem 272: 20650–20654.
73. Hunziker EB (1999) Articular cartilage repair: are the intrinsic biological
constraints undermining this process insuperable? Osteoarthritis Cartilage 7: 15–
28.
74. Stockwell RA (1979) Biology of cartilage cells; Harrison RJ, McMinn RMH,
editors. Cambridge: Cambridge University Press.
75. Shen B, Wei A, Tao H, Diwan AD, Ma DD (2009) BMP-2 enhances TGF-
beta3-mediated chondrogenic differentiation of human bone marrow multipo-
tent mesenchymal stromal cells in alginate bead culture. Tissue Eng Part A 15:
1311–1320.
76. Sekiya I, Colter DC, Prockop DJ (2001) BMP-6 enhances chondrogenesis in a
subpopulation of human marrow stromal cells. Biochem Biophys Res Commun
284: 411–418.
77. Shen B, Wei A, Whittaker S, Williams LA, Tao H, et al. (2010) The role of
BMP-7 in chondrogenic and osteogenic differentiation of human bone marrow
multipotent mesenchymal stromal cells in vitro. J Cell Biochem 109: 406–416.
78. Kim HJ, Im GI (2009) Combination of transforming growth factor-beta2 and
bone morphogenetic protein 7 enhances chondrogenesis from adipose tissue-
derived mesenchymal stem cells. Tissue Eng Part A 15: 1543–1551.
79. Lee S, Kim JH, Jo CH, Seong SC, Lee JC, et al. (2009) Effect of serum and
growth factors on chondrogenic differentiation of synovium-derived stromal
cells. Tissue Eng Part A 15: 3401–3415.
80. Rui YF, Du L, Wang Y, Lui PP, Tang TT, et al. (2010) Bone morphogenetic
protein 2 promotes transforming growth factor beta3-induced chondrogenesis of
human osteoarthritic synovium-derived stem cells. Chin Med J (Engl) 123:
3040–3048.
81. Li G, Corsi-Payne K, Zheng B, Usas A, Peng H, et al. (2009) The dose of growth
factors influences the synergistic effect of vascular endothelial growth factor on
bone morphogenetic protein 4-induced ectopic bone formation. Tissue Eng
Part A 15: 2123–2133.
82. Hanada K, Solchaga LA, Caplan AI, Hering TM, Goldberg VM, et al. (2001)
BMP-2 induction and TGF-beta 1 modulation of rat periosteal cell
chondrogenesis. J Cell Biochem 81: 284–294.
83. Kato Y, Iwamoto M, Koike T, Suzuki F, Takano Y (1988) Terminal
differentiation and calcification in rabbit chondrocyte cultures grown in
centrifuge tubes: regulation by transforming growth factor beta and serum
factors. Proc Natl Acad Sci U S A 85: 9552–9556.
84. Ballock RT, Heydemann A, Wakefield LM, Flanders KC, Roberts AB, et al.
(1993) TGF-beta 1 prevents hypertrophy of epiphyseal chondrocytes: regulation
of gene expression for cartilage matrix proteins and metalloproteases. Dev Biol
158: 414–429.
85. Yang X, Chen L, Xu X, Li C, Huang C, et al. (2001) TGF-beta/Smad3 signals
repress chondrocyte hypertrophic differentiation and are required for maintain-
ing articular cartilage. J Cell Biol 153: 35–46.
Synovium-Based Chondrogenesis for Cartilage Repair
PLOS ONE | www.plosone.org 14 January 2013 | Volume 8 | Issue 1 | e53086
